| 69.53 -1.46 (-2.06%) | 11-28 15:15 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 83.8  |
1-year : | 97.88 |
| Resists | First : | 71.75 |
Second : | 83.8 |
| Pivot price | 67.11 |
|||
| Supports | First : | 64.6 |
Second : | 60.18 |
| MAs | MA(5) : | 69.18 |
MA(20) : | 66.41 |
| MA(100) : | 70.5  |
MA(250) : | 72.51 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 83.8 |
D(3) : | 79.9 |
| RSI | RSI(14): 56.3 |
|||
| 52-week | High : | 100.85 | Low : | 47.45 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ LNTH ] has closed below upper band by 25.1%. Bollinger Bands are 9.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 71.43 - 71.7 | 71.7 - 71.97 |
| Low: | 67.29 - 67.62 | 67.62 - 67.94 |
| Close: | 70.46 - 70.96 | 70.96 - 71.47 |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Tue, 28 Nov 2023
A Look At The Fair Value Of Lantheus Holdings, Inc. (NASDAQ:LNTH) - Simply Wall St
Mon, 27 Nov 2023
Add Up The Pieces: IVOO Could Be Worth $99 - Nasdaq
Fri, 17 Nov 2023
Here is What to Know Beyond Why Lantheus Holdings, Inc. (LNTH) is a Trending Stock - Yahoo Finance
Wed, 08 Nov 2023
Lantheus to Present at the Jefferies London Healthcare Conference - Yahoo Finance
Mon, 06 Nov 2023
Is Trending Stock Lantheus Holdings, Inc. (LNTH) a Buy Now? - Nasdaq
Sat, 04 Nov 2023
Lantheus Holdings, Inc. (NASDAQ:LNTH) Q3 2023 Earnings Call Transcript - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers—Specialty & Generic
|
|
| Shares Out | 68 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 100.8 (%) |
| Shares Short | 4,840 (K) |
| Shares Short P.Month | 4,900 (K) |
| EPS | 1.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.19 |
| Profit Margin | 8.6 % |
| Operating Margin | 35.1 % |
| Return on Assets (ttm) | 8.7 % |
| Return on Equity (ttm) | 15.5 % |
| Qtrly Rev. Growth | 33.7 % |
| Gross Profit (p.s.) | 8.49 |
| Sales Per Share | 17.66 |
| EBITDA (p.s.) | 3.51 |
| Qtrly Earnings Growth | 118.5 % |
| Operating Cash Flow | 298 (M) |
| Levered Free Cash Flow | -270 (M) |
| PE Ratio | 46.45 |
| PEG Ratio | 0.3 |
| Price to Book value | 6.83 |
| Price to Sales | 3.94 |
| Price to Cash Flow | 15.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|